The company
Envoy Medical, Inc.
COCH · Nasdaq
COCH stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 4.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 3
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $16.3M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 33 (+1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Brent T. LucasChief Executive Officer | bought | 62,500at $0.40 | 12 Feb 2026filed 17 Feb 2026 |
| Brent T. LucasChief Executive Officer | bought | 37,500at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Brent T. LucasChief Executive Officer | bought | 62,500at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Charles BrynelsenDirector | bought | 1,000,000at $0.40 | 12 Feb 2026filed 17 Feb 2026 |
| Charles BrynelsenDirector | bought | 600,000at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Charles BrynelsenDirector | bought | 1,000,000at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Susan KantorDirector | bought | 96,150at $0.40 | 12 Feb 2026filed 17 Feb 2026 |
| Susan KantorDirector | bought | 57,690at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Susan KantorDirector | bought | 96,150at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Robert PotashnickInterim CFO | bought | 212,500at $0.40 | 12 Feb 2026filed 17 Feb 2026 |
| Robert PotashnickInterim CFO | bought | 127,500at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
| Robert PotashnickInterim CFO | bought | 212,500at $0.00 | 12 Feb 2026filed 17 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Nantahala Capital Management, LLCunchanged · filed 14 Aug 2026 | 7,650,000$6.0M | 00.0% |
| Bleichroeder LPunchanged · filed 13 Aug 2026 | 6,250,000$5.0M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 880,214$697K | -1,458−0.2% |
| DSG Capital Advisors, LLCunchanged · filed 6 Aug 2026 | 625,000$474K | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 541,729$429K | +19,905+3.8% |
| Focus Partners Wealthadded · filed 12 Aug 2026 | 425,310$337K | +212,655+100.0% |
| VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026 | 296,679$235K | +1,958+0.7% |
| UBS Group AGadded · filed 13 Aug 2026 | 190,838$151K | +120,379+170.8% |
| Arcus Capital Partners, LLCunchanged · filed 14 Aug 2026 | 187,573$149K | 00.0% |
| ExodusPoint Capital Management, LPnew · filed 14 Aug 2026 | 182,354$144K | +182,354 |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.